GlassScriptPhysician profile
Daniel J Leizman
NPI 1952300097
$1,199.94
in general payments reported to CMS, 2019-2025
8 companies · $268 in 2025
The $268 reported for 2025 was more than what a typical Physical Medicine & Rehabilitation provider received nationally (typical 2025 total: $138).
See the full distribution for Physical Medicine & Rehabilitation
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $116 · 2023: $682 · 2024: $134 · 2025: $268.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,084.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,084.40 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $662.60 | 2023 | Proclaim |
| Amgen INC. | $160.77 | 2022-2025 | Evenity, Prolia |
| Boston Scientific Corporation | $143.96 | 2025 | Intracept |
| Vertos Medical, INC. | $95.18 | 2024 | Mild Device Kit |
| Medtronic, INC. | $47.61 | 2024-2025 | Inceptiv, Intellis Adaptivestim |
| Pacira Pharmaceuticals Incorporated | $40.59 | 2025 | Iovera |
| Vertex Pharmaceuticals Incorporated | $29.63 | 2025 | |
| Curonix LLC | $19.60 | 2023 | Pns Freedom-4a Permanent Neurostimulator Receiver Kit Channel A |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Leizman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.